Beta-glucan attenuates inflammatory cytokine release and prevents acute lung injury in an experimental model of sepsis

被引:84
作者
Bedirli, Abdulkadir
Kerem, Mustafa
Pasaoglu, Hatice
Akyurek, Nalan
Tezcaner, Tugan
Elbeg, Sehri
Memis, Leyla
Sakrak, Omer
机构
[1] Gazi Univ, Sch Med, Dept Gen Surg, Ankara, Turkey
[2] Gazi Univ, Sch Med, Dept Biochem, Ankara, Turkey
[3] Gazi Univ, Sch Med, Dept Pathol, Ankara, Turkey
来源
SHOCK | 2007年 / 27卷 / 04期
关键词
inflammation; beta-glucan; cecal ligation and puncture; acute lung injury; ICAM-1;
D O I
10.1097/01.shk.0000245030.24235.f1
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Sepsis is one of the most important risk factors in acute respiratory distress syndrome (ARDS). beta-Glucan is a potent reticuloendothelial modulating agent, the immunobiological activity of which is mediated in part by an increase in the number and function of macrophages. In this study, we investigated the putative protective role of beta-glucan against sepsis-induced lung injury. Sepsis was induced by cecal ligation and puncture (CLP) in Wistar rats. The control group received saline, and the treatment groups received beta-glucan or beta-glucan + beta-1,3-D-glucanase. Five hours thereafter, plasma tumor necrosis factor (TNF) alpha, interleukin (IL) 1 beta, and IL-6 levels were determined. Presence of lung injury was determined via lung tissue myeloperoxidase (MPO) activity, intercellular adhesion molecule (ICAM) 1 levels, and histopathological examination at 18 h after CLP. In a separate set of experiments, survival was monitored for 7 days after CLP. beta-Glucan treatment led to a significant increase in survival rate (63% in glucan-treated rats vs 38% in saline-treated rats). Administration of the beta-glucan inhibitor abrogated beta-glucan's survival benefit (50%). After CLP, plasma TNF-alpha, IL-1 beta, and IL-6 concentrations were increased in control animals. When beta-glucan was administered, it completely blocked the elevation of TNF-alpha, IL-1 beta, and IL-6. Administration of beta-1,3-D-glucanase suppressed glucan-induced decrease in cytokines. Animals treated with beta-glucan showed a significant reduction in lung injury score, a marked decrease in ICAM-1 expression, and a significant decrease in MPO levels. In contrast, beta-1,3-D-glucanase caused a significantly increased MPO and ICAM-1 levels in the lung. These data reveal that beta-glucan treatment improved the course of CLP-induced peritonitis and attenuated the lung injury. Administration of beta-glucanase inhibited the beta-glucan activity and resulted in enhanced lung injury.
引用
收藏
页码:397 / 401
页数:5
相关论文
共 35 条
[1]  
BABAYIGIT H, 1995, INTENS CARE MED, V31, P865
[2]  
BABINEAU TJ, 1994, ARCH SURG-CHICAGO, V129, P1204
[3]   Prevention of intraperitoneal adhesions and abscesses by polysaccharides isolated from Phellinus spp in a rat peritonitis model [J].
Bae, J ;
Ahn, S ;
Yim, H ;
Jang, K ;
Jin, HK .
ANNALS OF SURGERY, 2005, 241 (03) :534-540
[4]   Immunopharmacology - Immunomodulation and immunotherapy [J].
Ballow, M ;
Nelson, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (22) :2008-2017
[5]   Prevention of intraperitoneal adhesion formation using beta-glucan after ileocolic anastomosis in a rat bacterial peritonitis model [J].
Bedirli, A ;
Gokahmetoglu, S ;
Sakrak, O ;
Ersoz, N ;
Ayangil, D ;
Esin, H .
AMERICAN JOURNAL OF SURGERY, 2003, 185 (04) :339-343
[6]   Mechanisms of early pulmonary neutrophil sequestration in ventilator-induced lung injury in mice [J].
Choudhury, S ;
Wilson, MR ;
Goddard, ME ;
O'Dea, KP ;
Takata, M .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2004, 287 (05) :L902-L910
[7]   Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations [J].
Dellinger, EP ;
Babineau, TJ ;
Bleicher, P ;
Kaiser, AB ;
Seibert, GB ;
Postier, RG ;
Vogel, SB ;
Norman, J ;
Kaufman, D ;
Galandiuk, S ;
Condon, RE .
ARCHIVES OF SURGERY, 1999, 134 (09) :977-983
[8]  
Essani NA, 1997, J IMMUNOL, V158, P5941
[9]   Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein [J].
Fisher, CJ ;
Agosti, JM ;
Opal, SM ;
Lowry, SF ;
Balk, RA ;
Sadoff, JC ;
Abraham, E ;
Schein, RMH ;
Benjamin, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) :1697-1702
[10]  
FRIES JWU, 1993, AM J PATHOL, V143, P725